Glenmark receives ANDA approval for Clobetasol Propionate Foam
18 February 2019 | News
It is a generic version of Olux®1 Foam, 0.05%, of Mylan Pharmaceuticals
Glenmark Pharmaceuticals has been granted final approval by the United States Food & Drug Administration (U.S. FDA) for Clobetasol Propionate Foam, 0.05%, a generic version of Olux®1 Foam, 0.05%, of Mylan Pharmaceuticals, Inc.
According to IQVIATM sales data for the 12 month period ending December 2018, the Olux® Foam, 0.05% market2 achieved annual sales of approximately $50.9 million.
Glenmark’s current portfolio consists of 150 products authorized for distribution in the U.S. marketplace and 52 ANDA’s pending approval with the U.S. FDA.
